United States Patent 4,559,222: Scope, Claim Architecture, and US Patent Landscape

US Patent 4,559,222 protects a specific mineral-oil/polyisobutylene (MO/PIB) matrix and two use-classes built around it: (1) a matrix composition for drug delivery and (2) transdermal therapeutic systems that use that matrix in a reservoir/adhesive architecture with a release-rate controlling membrane. The core novelty is the combination of (a) MO/PIB ratio thresholds, (b) minimum colloidal silicon dioxide loading (at least 6% by weight), (c) high viscosity specification (at least 1.5 × 10^7 poise), and (d) defined drug solubility state for a “moderately mineral oil soluble drug” (including drug amounts at or above saturation concentration). The claim set also locks in specific drug examples (with clonidine singled out for quantitative permeability and release thresholds) and defines PIB molecular weight bands.

What exactly does the patent claim protect?

Composition-of-matter (matrix) scope

The claims center on a matrix composition that is “suitable for use as a matrix in a drug delivery system” and is defined by four coupled technical requirements:

Claim element	Requirement (minimums / bounds)	Claim coverage
Base polymer/plasticizer system	Mineral oil + polyisobutylene	Claim 1; Claim 12; Claim 8 (system layers)
Solids/particulate load	At least 6% colloidal silicon dioxide	Claim 1; Claim 8; Claim 12
Formulation ratio	MO/PIB ratio at least 1.0	Claim 1; system claims also include MO/PIB at least 1.2; dependent claims refine
Rheology	Viscosity at least 1.5 × 10^7 poise	Claim 1; Claim 8; Claim 12

Drug “solubility state” scope

The claims treat the drug as a “moderately mineral oil soluble drug,” dispersed in the matrix. Two regimes appear in the dependent claims:

Upper and lower bounds by concentration:
- Up to about 40% drug by dispersion: Claim 2
- Drug level “between the saturation concentration … and about 20%”: Claim 3
Transdermal system regime:
- Reservoir and adhesive layers contain the drug at “a concentration above the saturation concentration of said drug in said layer”: Claim 8

That solubility-state limitation is critical because it constrains infringement to formulations where the drug content is not merely “dissolved,” but is pushed to saturation or above saturation in the relevant layers.

Transdermal therapeutic system scope

Claim 8 transitions from the matrix composition to a full transdermal system architecture:

Drug reservoir layer + adhesive layer
Drug release controlling membrane between reservoir and adhesive
Both reservoir and adhesive layers include:
- at least about 6% colloidal silicon dioxide
- viscosity at least 1.5 × 10^7 poise
- MO/PIB ratio in reservoir and adhesive at least 1.2

Dependent claims then extend system-level ratios and performance metrics:

Membrane contains mineral oil (Claim 9)
Overall MO/PIB ratio in the transdermal system at least 1.4 (Claim 9)
Clonidine-specific performance:
- In vitro release rate to infinite sink at least 2.0 μg/cm²-hr (Claim 11)

PIB molecular weight scope

The patent specifies PIB molecular weight bands for the base polymer component:

PIB average molecular weight about 35,000 to about 1,500,000 (Claim 15)
Dependent confirmations: Claims 16–18 mirror this same band for different dependent claim chains

This narrows the claim protection to PIB grades falling in that weight range.

How broad are the claim ranges and what are the key “levers” for infringement?

The three formulation levers

Colloidal silicon dioxide loading: at least 6%
MO/PIB ratio:
- composition claim floor: at least 1.0
- transdermal system reservoir/adhesive floors: at least 1.2
- system overall floor: at least 1.4
Viscosity: at least 1.5 × 10^7 poise

These three interact: the higher MO/PIB and higher silicon dioxide levels are paired with a high-viscosity matrix. Claim drafting suggests that the invention is not just “add silica” but “add silica at a loading that raises and stabilizes properties within a viscosity window while maintaining MO/PIB ratio thresholds.”

Drug loading levers

For the matrix composition chain:

Drug can be dispersed at up to ~40% (Claim 2)
But the narrower dependent claim specifies from saturation to ~20% (Claim 3)

For the transdermal system chain:

Drug concentration in reservoir/adhesive is above saturation (Claim 8), which is not the same as “up to saturation” and is likely a different formulation regime in practice.

Drug identity and performance levers

The patent lists many drugs that are “selected from” a defined group (Claim 5, Claim 10). Clonidine is separately quantified:

Clonidine permeability through the composition at least 1.0 × 10^-4 μg/cm·sec (Claim 6)
Clonidine permeability tied to higher MO/PIB (Claim 7)
Clonidine in vitro release to infinite sink at least 2.0 μg/cm²-hr (Claim 11)

This creates a second infringement path:

A product that matches the matrix/system structural limits could still avoid clonidine-specific sub-claims if it fails the quantitative permeability/release thresholds.
Conversely, a clonidine product that meets those quantitative performance minima can be forced into stronger coverage.

PIB molecular weight lever

Even if a product matches silica loading, MO/PIB ratio, and viscosity, the claim can fail if the PIB molecular weight falls outside the specified range.

Claim-by-claim map: what each claim adds

Independent anchor

Claim 1 is the independent matrix composition core:
- Mineral oil + polyisobutylene
- at least 6% colloidal silicon dioxide
- MO/PIB ratio at least 1.0
- viscosity at least 1.5 × 10^7 poise
- includes a “moderately mineral oil soluble drug” dispersed in the matrix

Dependent claims (matrix chain)

Claim 2: drug dispersed up to about 40%
Claim 3: drug present between saturation concentration and about 20%
Claim 4:
- MO/PIB at least 1.2
- silicon dioxide at least 7.5%
Claim 5: drug identity list (15 examples plus others, including clonidine, scopolamine, propranolol, estradiol, phenylpropanolamine, ouabain, salbutamol, guanabenz, labetolol, atropine, haloperidol, bromocryptine, chloropheniramine, metrifonate, isosorbide dinitrate, nitroglycerin)
Claim 6: clonidine permeability at least 1.0 × 10^-4 μg/cm·sec
Claim 7: clonidine plus MO/PIB at least 1.2
Claim 15: PIB molecular weight about 35,000 to about 1,500,000

Transdermal therapeutic system chain

Claim 8: system with reservoir + adhesive + release-rate controlling membrane:
- drug concentration above saturation in reservoir/adhesive layers
- reservoir and adhesive layers include:
- at least about 6% colloidal silicon dioxide
- viscosity at least 1.5 × 10^7 poise
- MO/PIB ratio in reservoir and adhesive at least 1.2
Claim 9:
- release-rate controlling membrane contains mineral oil
- overall system MO/PIB at least 1.4
Claim 10: drug identity list (matches Claim 5 scope)
Claim 11: clonidine in vitro release to infinite sink at least 2.0 μg/cm²-hr
Claim 12: matrix composition improvement restating the same “gel of mineral oil and polyisobutylene” concept:
- at least about 6% colloidal silicon dioxide
- MO/PIB ratio at least 1.0
- viscosity at least about 1.5 × 10^7 poise
Claim 13: refines Claim 12:
- MO/PIB at least about 1.2
- colloidal silicon dioxide between 6 and 10%
- drug between saturation concentration and about 40%
Claim 14: clonidine matrix permeability at least 1 × 10^-4 μg/cm·sec (ties back to the clonidine quantitative threshold)
Claims 16–18: PIB molecular weight confirmation across different claim dependencies (same band as Claim 15)

What is the patent landscape risk profile in the US?

How this patent would typically sit in the landscape

The patent’s structure indicates it targets formulation and system performance for transdermal delivery using MO/PIB matrices loaded with colloidal silicon dioxide. In US practice, this kind of claim set usually creates a landscape where:

Generic or “design-around” formulations must avoid at least one of the tight coupling elements:
- silica loading below 6%
- MO/PIB ratio below the relevant threshold
- viscosity below 1.5 × 10^7 poise
- PIB molecular weight outside the specified range
- drug concentration not at or above saturation in reservoir/adhesive layers (for system claims)
- clonidine permeability/release not meeting quantitative thresholds (for clonidine performance sub-claims)

Practical “avoidance” patterns implied by the claim set

To reduce likelihood of literal infringement, developers would typically attempt at least one of:

reduce colloidal silicon dioxide below 6% (claims are anchored on “at least 6%”)
adjust MO/PIB ratio below 1.0 for composition claims, below 1.2 for system reservoir/adhesive, or below 1.4 overall for system claims
reduce viscosity below 1.5 × 10^7 poise via formulation rebalancing
use PIB outside the molecular weight band (about 35,000 to about 1,500,000)
avoid the saturation/above-saturation drug loading state in the relevant reservoir/adhesive layers
for clonidine, fail the permeability or release quantitative thresholds

Drug-list coverage as breadth multiplier

The drug identity list is broad enough to cover many transdermal candidates, including multiple salts and pharmacologic classes. That widens enforcement leverage: a competitor cannot avoid the patent merely by selecting a different drug among those enumerated, as long as all formulation/system limitations are met.

Scope summary: strongest coverage categories

Category A: MO/PIB matrix composition with silica and viscosity thresholds

Strongest and most straightforward coverage:

composition with MO/PIB matrix
at least 6% colloidal silicon dioxide
MO/PIB ratio at least 1.0
viscosity at least 1.5 × 10^7 poise
moderately mineral oil soluble drug dispersed (with concentration limits depending on which dependent claim is asserted)

Category B: transdermal system reservoir/adhesive with silica, high viscosity, and saturation dosing

Stronger system-level constraints:

reservoir and adhesive both contain silica at least 6%
both have viscosity at least 1.5 × 10^7 poise
MO/PIB ratio in reservoir/adhesive at least 1.2
drug concentration in reservoir/adhesive above saturation
release-rate controlling membrane between layers
membrane contains mineral oil (Claim 9 dependent)
overall MO/PIB at least 1.4 (Claim 9 dependent)

Category C: clonidine quantitative performance hooks

For clonidine specifically, the patent adds measured permeability and release requirements:

permeability at least 1.0 × 10^-4 μg/cm·sec (Claims 6 and 14)
in vitro release rate to infinite sink at least 2.0 μg/cm²-hr (Claim 11)

These performance hooks are likely to be central in any infringement proof strategy because they reduce “argument about formulation only” and push toward measurable product attributes.

Key Takeaways

US 4,559,222 protects MO/PIB transdermal matrix and system architectures defined by a coupled set of measurable formulation parameters: silicon dioxide (>=6%), MO/PIB ratio (>=1.0 composition; >=1.2 reservoir/adhesive; >=1.4 overall system), and viscosity (>=1.5 × 10^7 poise).
Claim scope is widened by an enumerated drug set (including clonidine, scopolamine, propranolol, estradiol, salbutamol, labetolol, atropine, nitroglycerin, and others).
Clonidine is reinforced with quantitative performance limitations: permeability >= 1.0 × 10^-4 μg/cm·sec and in vitro release to infinite sink >= 2.0 μg/cm²-hr, tightening infringement exposure for clonidine products meeting the base formulation.
The patent adds a PIB molecular weight constraint (about 35,000 to about 1,500,000), creating an additional design-around axis beyond silica, ratio, and viscosity.

FAQs

1) Which claims are the broadest in US 4,559,222?

The breadth anchor is Claim 1 for composition-of-matter (MO/PIB matrix with >=6% colloidal silicon dioxide, MO/PIB >=1.0, viscosity >=1.5 × 10^7 poise). Claim 8 is the broad system anchor for transdermal architecture under the saturation dosing and coupled formulation constraints.

2) Does the patent cover transdermal systems only, or also standalone matrices?

Both. It covers standalone matrix compositions (Claims 1, 12 and dependent refinement) and transdermal therapeutic systems (Claim 8 and dependents).

3) How is “moderately mineral oil soluble drug” used in the claims?

It is the functional drug descriptor used across the formulations. Dependent claims then specify concentration regimes: up to about 40%, or between saturation concentration and about 20% for the matrix chain, and above saturation for the reservoir/adhesive layers in the system chain.

4) What are the main numeric thresholds that competitors must manage?

The core numeric thresholds are: >=6% colloidal silicon dioxide, viscosity >= 1.5 × 10^7 poise, MO/PIB ratio >=1.0 (composition), >=1.2 (reservoir/adhesive), and >=1.4 overall (system). For clonidine products, permeability and release thresholds add further constraints.

5) Does PIB molecular weight matter to infringement?

Yes. Claims 15 to 18 restrict PIB to an average molecular weight range of about 35,000 to about 1,500,000.

References

[1] United States Patent 4,559,222.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2717184	⤷ Start Trial
Australia	558304	⤷ Start Trial
Belgium	899444	⤷ Start Trial
Canada	1217139	⤷ Start Trial
Switzerland	666190	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,559,222

Summary for Patent: 4,559,222